{"id":809851,"date":"2025-02-06T08:22:15","date_gmt":"2025-02-06T13:22:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/"},"modified":"2025-02-06T08:22:15","modified_gmt":"2025-02-06T13:22:15","slug":"nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/","title":{"rendered":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n \u2022 Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York<\/span>February 10<\/span>th<\/sup>-12th<\/sup><\/i>\n <\/p>\n

\n
\n WILMINGTON, Del.<\/span>
\n <\/span>, Feb. 6, 2025<\/span><\/span> \/PRNewswire\/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE”), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt<\/span>, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals\u00a0will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11<\/span>th<\/sup>-12th<\/sup>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/NRx
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The presentation is scheduled forWednesday, February 12<\/span>th<\/sup>, from 9:20 \u2013 9:50 AM EST<\/span><\/b>. A live webcast will be accessible on NRX Events<\/a>, within the Investor Relations section of the Company’s website. A replay of the webcast will also be available for 30 days following the event.<\/p>\n

Management will also be available for one-on-one meetings in New York<\/span> from February 10<\/span>th<\/sup>-12th<\/sup>. To schedule meetings in New York<\/span> or at the BIO CEO & Investor Conference, please contact sebastian.gomez@astrpartners.com<\/a>.<\/u><\/p>\n

\n About NRx Pharmaceuticals<\/b>\n <\/p>\n

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.<\/p>\n

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.<\/p>\n

\n About HOPE Therapeutics, Inc.<\/b>\n <\/p>\n

HOPE Therapeutics, Inc. (www.hopetherapeutics.com<\/a><\/u>) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional\u00a0 psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.<\/p>\n

\n Notice Regarding Forward-Looking Statements<\/b>\n <\/p>\n

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including risks arising from uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, liquidity, HOPE Therapeutic’s ability to consummate the acquisitions of providers for its national network, the Company’s ability to raise adequate capital to fund such acquisitions, and the Company’s ability to spin-off HOPE Therapeutics.\u00a0 More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http:\/\/www.sec.gov<\/a>. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n For further information:
<\/b>
\n Matthew Duffy<\/span>
\n
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics<\/span>, Inc.
mduffy@nrxpharma.com<\/a><\/p>\n

\n

\n
\n \"HOPE
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025-302369970.html<\/a><\/p>\n

SOURCE NRx Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire \u2022 Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New YorkFebruary 10th-12th WILMINGTON, Del. , Feb. 6, 2025 \/PRNewswire\/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE”), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals\u00a0will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11th-12th. The presentation is scheduled forWednesday, February 12th, from 9:20 \u2013 9:50 AM EST. A live webcast will … <\/p>\n

Continue reading “NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809851","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire \u2022 Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New YorkFebruary 10th-12th WILMINGTON, Del. , Feb. 6, 2025 \/PRNewswire\/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE”), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals\u00a0will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11th-12th. The presentation is scheduled forWednesday, February 12th, from 9:20 \u2013 9:50 AM EST. A live webcast will … Continue reading "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T13:22:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025\",\"datePublished\":\"2025-02-06T13:22:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/\"},\"wordCount\":829,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1734122\\\/NRX_Logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/\",\"name\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1734122\\\/NRX_Logo_Logo.jpg\",\"datePublished\":\"2025-02-06T13:22:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1734122\\\/NRX_Logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1734122\\\/NRX_Logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/","og_locale":"en_US","og_type":"article","og_title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk","og_description":"PR Newswire \u2022 Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New YorkFebruary 10th-12th WILMINGTON, Del. , Feb. 6, 2025 \/PRNewswire\/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE”), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals\u00a0will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11th-12th. The presentation is scheduled forWednesday, February 12th, from 9:20 \u2013 9:50 AM EST. A live webcast will … Continue reading \"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T13:22:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025","datePublished":"2025-02-06T13:22:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/"},"wordCount":829,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/","name":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg","datePublished":"2025-02-06T13:22:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1734122\/NRX_Logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics\u2122, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809851"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}